ABC-294640 is primarily investigated for its potential therapeutic applications, particularly in the field of oncology. It functions as a selective sphingosine kinase 2 (SphK2) inhibitor, which plays a role in regulating cell growth, survival, and inflammation. By inhibiting SphK2, ABC-294640 has shown promise in reducing tumor growth and inducing apoptosis in various cancer models, including breast, prostate, and liver cancers. Additionally, it is being studied for its anti-inflammatory properties, which could be beneficial in treating conditions like rheumatoid arthritis and inflammatory bowel disease. Research also explores its potential in managing fibrosis and other diseases linked to abnormal cell proliferation and inflammation. Its ability to modulate sphingolipid metabolism makes it a compound of interest in both cancer therapy and inflammatory disorders.